journal article Mar 23, 2018

Cancer immunotherapy using checkpoint blockade

View at Publisher Save 10.1126/science.aar4060
Abstract
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers. This can be achieved by antibodies blocking the cytotoxic T lymphocyte–associated protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination. The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints. Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse. Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways. New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.
Topics

No keywords indexed for this article. Browse by subject →

References
61
[2]
Enhancement of Antitumor Immunity by CTLA-4 Blockade

Dana R. Leach, Matthew F. Krummel, James P. Allison

Science 10.1126/science.271.5256.1734
[3]
CTLA-4 can function as a negative regulator of T cell activation

Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al.

Immunity 10.1016/1074-7613(94)90071-x
[6]
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A. Postow, Robert Sidlow, Matthew D. Hellmann

New England Journal of Medicine 10.1056/nejmra1703481
[9]
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O'Day et al.

Clinical Cancer Research 10.1158/1078-0432.ccr-09-1624
[10]
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven J. O'Day, David F. McDermott et al.

New England Journal of Medicine 10.1056/nejmoa1003466
[11]
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, Luc Thomas, Igor Bondarenko et al.

New England Journal of Medicine 10.1056/nejmoa1104621
[15]
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Y. Ishida, Y. Agata, K. Shibahara et al.

The EMBO Journal 10.1002/j.1460-2075.1992.tb05481.x
[19]
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Angel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al.

Cell Reports 10.1016/j.celrep.2017.04.031
[21]
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas et al.

Cancer Discovery 10.1158/2159-8290.cd-16-1223
[23]
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez et al.

New England Journal of Medicine 10.1056/nejmoa1709684
[25]
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.

New England Journal of Medicine 10.1056/nejmoa1200690
[26]
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al.

New England Journal of Medicine 10.1056/nejmoa1501824
[29]
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al.

New England Journal of Medicine 10.1056/nejmoa1411087
[32]
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George Blumenschein, Jerome Fayette et al.

New England Journal of Medicine 10.1056/nejmoa1602252
[34]
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al.

New England Journal of Medicine 10.1056/nejmoa1613683
[36]
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, David F. McDermott et al.

New England Journal of Medicine 10.1056/nejmoa1510665
[37]
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Samra Turajlic, Kevin Litchfield, Hang Xu et al.

The Lancet Oncology 10.1016/s1470-2045(17)30516-8
[38]
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A. Wargo et al.

Cell 10.1016/j.cell.2017.01.017
[40]
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Janis M. Taube, Robert A. Anders, Geoffrey D. Young et al.

Science Translational Medicine 10.1126/scitranslmed.3003689
[43]
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan, Andrew J. S. Furness, Rachel Rosenthal et al.

Science 10.1126/science.aaf1490
[44]
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

Marta Łuksza, Nadeem Riaz, Vladimir Makarov et al.

Nature 10.1038/nature24473
[45]
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley et al.

Cell 10.1016/j.cell.2017.10.001
[47]
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Willy Hugo, Jesse M. Zaretsky, Lu Sun et al.

Cell 10.1016/j.cell.2016.02.065
[49]
PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al.

Nature 10.1038/nature13954

Showing 50 of 61 references

Cited By
5,757
Signal Transduction and Targeted Th...
Nature
Advances in Immunotherapy in Hepatocellular Carcinoma

Matthew Bloom, Sourav Podder · 2025

International Journal of Molecular...
Journal of Cardiovascular Developme...
Metrics
5,757
Citations
61
References
Details
Published
Mar 23, 2018
Vol/Issue
359(6382)
Pages
1350-1355
Funding
National Cancer Institute Award: R35 CA197633
Parker Institute for Cancer Immunotherapy Award: N/A
Ludwig Cancer Research Award: N/A
Cite This Article
Antoni Ribas, Jedd D. Wolchok (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350-1355. https://doi.org/10.1126/science.aar4060
Related

You May Also Like

Electric Field Effect in Atomically Thin Carbon Films

K. S. Novoselov, A. K. Geim · 2004

61,289 citations

Optimization by Simulated Annealing

S. Kirkpatrick, C. D. Gelatt · 1983

44,123 citations

Emergence of Scaling in Random Networks

Albert-László Barabási, Réka Albert · 1999

35,859 citations

Judgment under Uncertainty: Heuristics and Biases

Amos Tversky, Daniel Kahneman · 1974

27,432 citations

The Tragedy of the Commons

Garrett Hardin · 1968

22,676 citations